Somewhat Positive Press Coverage Somewhat Unlikely to Impact La Jolla Pharmaceutical (LJPC) Share Price
Press coverage about La Jolla Pharmaceutical (NASDAQ:LJPC) has been trending somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. La Jolla Pharmaceutical earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.9099410627536 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Benzinga’s Top Upgrades, Downgrades For August 30, 2017 – Benzinga (benzinga.com)
- Traders Are Circling La Jolla Pharmaceutical Co (LJPC), What Do the Numbers Tell Us? – Financial News Review (finnewsreview.com)
- La Jolla Pharmaceutical Co (LJPC) Sees AroonDown Showing Strong Downward Momentum – FLBC News (flbcnews.com)
- La Jolla Pharmaceutical Company (LJPC) Now Covered by J P Morgan Chase & Co (americanbankingnews.com)
- Reversal Time? La Jolla Pharmaceutical Co (LJPC) Schaff Indicator Nearing Key Levels – Evergreen Caller (evergreencaller.com)
La Jolla Pharmaceutical (LJPC) opened at 34.252 on Thursday. The company has a 50-day moving average of $31.27 and a 200 day moving average of $29.49. La Jolla Pharmaceutical has a 52 week low of $14.63 and a 52 week high of $39.28. The company’s market cap is $757.76 million.
La Jolla Pharmaceutical (NASDAQ:LJPC) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.12) by $0.09. La Jolla Pharmaceutical had a negative net margin of 12,692.37% and a negative return on equity of 91.66%. During the same quarter in the previous year, the business earned ($0.90) earnings per share. On average, equities analysts forecast that La Jolla Pharmaceutical will post ($4.99) EPS for the current fiscal year.
Several equities analysts recently commented on the stock. ValuEngine raised shares of La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Zacks Investment Research downgraded shares of La Jolla Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. BidaskClub raised shares of La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Wednesday, August 9th. Jefferies Group LLC reissued a “buy” rating and issued a $40.00 price objective on shares of La Jolla Pharmaceutical in a research note on Tuesday, July 25th. Finally, SunTrust Banks, Inc. reissued a “buy” rating and issued a $57.00 price objective on shares of La Jolla Pharmaceutical in a research note on Monday, May 22nd. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. La Jolla Pharmaceutical presently has a consensus rating of “Buy” and a consensus price target of $51.00.
TRADEMARK VIOLATION WARNING: This story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.watchlistnews.com/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-la-jolla-pharmaceutical-ljpc-share-price/1533983.html.
La Jolla Pharmaceutical Company Profile
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).
Receive News & Ratings for La Jolla Pharmaceutical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical Company and related companies with Analyst Ratings Network's FREE daily email newsletter.